Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
Semisynthetic aminoglycoside antibiotics: Development and enzymatic modifications.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Kondo S, Hotta K.
PMID: 11810483
J Infect Chemother. 1999 Mar;5(1):1-9. doi: 10.1007/s101560050001.

The critical resistance mechanisms of aminoglycoside antibiotics in bacteria of clinical importance are the enzymatic N-acetylation, O-phosphorylation, and O-nucleotidylation that generally result in the inactivation of aminoglycosides. To overcome such resistance mechanisms, dibekacin (3',4'-dideoxykanamycin B) was developed as the...

Cite
Kondo S, Hotta K. Semisynthetic aminoglycoside antibiotics: Development and enzymatic modifications. J Infect Chemother. 1999;5(1):1-9doi: 10.1007/s101560050001.
Kondo, S., & Hotta, K. (1999). Semisynthetic aminoglycoside antibiotics: Development and enzymatic modifications. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 5(1), 1-9. https://doi.org/10.1007/s101560050001
Kondo, S., and Hotta, Kunimoto. "Semisynthetic aminoglycoside antibiotics: Development and enzymatic modifications." Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy vol. 5,1 (1999): 1-9. doi: https://doi.org/10.1007/s101560050001
Kondo S, Hotta K. Semisynthetic aminoglycoside antibiotics: Development and enzymatic modifications. J Infect Chemother. 1999 Mar;5(1):1-9. doi: 10.1007/s101560050001. PMID: 11810483.
Copy Download .nbib Format: NLM
Identification of Anti-Persister Activity against Uropathogenic Escherichia coli from a Clinical Drug Library.

Antibiotics (Basel, Switzerland)

Niu H, Cui P, Shi W, Zhang S, Feng J, Wang Y, Sullivan D, Zhang W, Zhu B, Zhang Y.
PMID: 27025620
Antibiotics (Basel). 2015 May 12;4(2):179-87. doi: 10.3390/antibiotics4020179.

Uropathogenic E. coli is a major cause of urinary tract infections (UTIs), but current antibiotics do not always effectively clear the persistent infection. To identify drugs that eliminate uropathogenic E. coli persisters, we screened a clinical drug library consisting...

Cite
Niu H, Cui P, Shi W, et al. Identification of Anti-Persister Activity against Uropathogenic Escherichia coli from a Clinical Drug Library. Antibiotics (Basel). 2015;4(2):179-87doi: 10.3390/antibiotics4020179.
Niu, H., Cui, P., Shi, W., Zhang, S., Feng, J., Wang, Y., Sullivan, D., Zhang, W., Zhu, B., & Zhang, Y. (2015). Identification of Anti-Persister Activity against Uropathogenic Escherichia coli from a Clinical Drug Library. Antibiotics (Basel, Switzerland), 4(2), 179-87. https://doi.org/10.3390/antibiotics4020179
Niu, Hongxia, et al. "Identification of Anti-Persister Activity against Uropathogenic Escherichia coli from a Clinical Drug Library." Antibiotics (Basel, Switzerland) vol. 4,2 (2015): 179-87. doi: https://doi.org/10.3390/antibiotics4020179
Niu H, Cui P, Shi W, Zhang S, Feng J, Wang Y, Sullivan D, Zhang W, Zhu B, Zhang Y. Identification of Anti-Persister Activity against Uropathogenic Escherichia coli from a Clinical Drug Library. Antibiotics (Basel). 2015 May 12;4(2):179-87. doi: 10.3390/antibiotics4020179. PMID: 27025620; PMCID: PMC4790332.
Copy Download .nbib Format: NLM
Cytotoxicity of five fluoroquinolone and two nonsteroidal anti-inflammatory benzalkonium chloride-free ophthalmic solutions in four corneoconjunctival cell lines.

Clinical ophthalmology (Auckland, N.Z.)

Ayaki M, Iwasawa A, Soda M, Yaguchi S, Koide R.
PMID: 20922036
Clin Ophthalmol. 2010 Sep 20;4:1019-24. doi: 10.2147/opth.s12452.

PURPOSE: Epithelial disorders after eye surgery can result in visual deterioration and patient discomfort. Such disorders may be caused by drug toxicity. In the present study, we evaluated the toxicity of ophthalmic solutions, with or without benzalkonium chloride (BAK)...

Cite
Ayaki M, Iwasawa A, Soda M, et al. Cytotoxicity of five fluoroquinolone and two nonsteroidal anti-inflammatory benzalkonium chloride-free ophthalmic solutions in four corneoconjunctival cell lines. Clin Ophthalmol. 2010;4:1019-24doi: 10.2147/opth.s12452.
Ayaki, M., Iwasawa, A., Soda, M., Yaguchi, S., & Koide, R. (2010). Cytotoxicity of five fluoroquinolone and two nonsteroidal anti-inflammatory benzalkonium chloride-free ophthalmic solutions in four corneoconjunctival cell lines. Clinical ophthalmology (Auckland, N.Z.), 41019-24. https://doi.org/10.2147/opth.s12452
Ayaki, Masahiko, et al. "Cytotoxicity of five fluoroquinolone and two nonsteroidal anti-inflammatory benzalkonium chloride-free ophthalmic solutions in four corneoconjunctival cell lines." Clinical ophthalmology (Auckland, N.Z.) vol. 4 (2010): 1019-24. doi: https://doi.org/10.2147/opth.s12452
Ayaki M, Iwasawa A, Soda M, Yaguchi S, Koide R. Cytotoxicity of five fluoroquinolone and two nonsteroidal anti-inflammatory benzalkonium chloride-free ophthalmic solutions in four corneoconjunctival cell lines. Clin Ophthalmol. 2010 Sep 20;4:1019-24. doi: 10.2147/opth.s12452. PMID: 20922036; PMCID: PMC2946991.
Copy Download .nbib Format: NLM
Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens.

Clinical pharmacology : advances and applications

Matsumoto T.
PMID: 25298740
Clin Pharmacol. 2014 Sep 26;6:139-48. doi: 10.2147/CPAA.S44377. eCollection 2014.

Arbekacin sulfate (ABK), an aminoglycoside antibiotic, was discovered in 1972 and was derived from dibekacin to stabilize many common aminoglycoside modifying enzymes. ABK shows broad antimicrobial activities against not only Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) but also...

Cite
Matsumoto T. Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens. Clin Pharmacol. 2014;6:139-48doi: 10.2147/CPAA.S44377.
Matsumoto, T. (2014). Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens. Clinical pharmacology : advances and applications, 6139-48. https://doi.org/10.2147/CPAA.S44377
Matsumoto, Tetsuya. "Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens." Clinical pharmacology : advances and applications vol. 6 (2014): 139-48. doi: https://doi.org/10.2147/CPAA.S44377
Matsumoto T. Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens. Clin Pharmacol. 2014 Sep 26;6:139-48. doi: 10.2147/CPAA.S44377. eCollection 2014. PMID: 25298740; PMCID: PMC4186621.
Copy Download .nbib Format: NLM
Dibekacin assay in serum by automated fluorescence polarization immunoassay (Abbott Tdx): comparison with high-performance liquid chromatography, substrate-labelled fluorescent immunoassay and radioimmunoassay.

Journal of pharmaceutical and biomedical analysis

Rollman B, Van der Auwera P, Tulkens PM.
PMID: 16867630
J Pharm Biomed Anal. 1986;4(1):53-61. doi: 10.1016/0731-7085(86)80023-1.

An immunoassay based on fluorescence polarization detection (FPIA) has been recently adapted for dibekacin. This has been compared with a reference method (high-performance liquid chromatography), and two other methods used in clinical laboratories for monitoring this aminoglycoside, namely substrate-labelled...

Cite
Rollman B, Van der Auwera P, Tulkens PM. Dibekacin assay in serum by automated fluorescence polarization immunoassay (Abbott Tdx): comparison with high-performance liquid chromatography, substrate-labelled fluorescent immunoassay and radioimmunoassay. J Pharm Biomed Anal. 1986;4(1):53-61doi: 10.1016/0731-7085(86)80023-1.
Rollman, B., Van der Auwera, P., & Tulkens, P. M. (1986). Dibekacin assay in serum by automated fluorescence polarization immunoassay (Abbott Tdx): comparison with high-performance liquid chromatography, substrate-labelled fluorescent immunoassay and radioimmunoassay. Journal of pharmaceutical and biomedical analysis, 4(1), 53-61. https://doi.org/10.1016/0731-7085(86)80023-1
Rollman, B, et al. "Dibekacin assay in serum by automated fluorescence polarization immunoassay (Abbott Tdx): comparison with high-performance liquid chromatography, substrate-labelled fluorescent immunoassay and radioimmunoassay." Journal of pharmaceutical and biomedical analysis vol. 4,1 (1986): 53-61. doi: https://doi.org/10.1016/0731-7085(86)80023-1
Rollman B, Van der Auwera P, Tulkens PM. Dibekacin assay in serum by automated fluorescence polarization immunoassay (Abbott Tdx): comparison with high-performance liquid chromatography, substrate-labelled fluorescent immunoassay and radioimmunoassay. J Pharm Biomed Anal. 1986;4(1):53-61. doi: 10.1016/0731-7085(86)80023-1. PMID: 16867630.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries